Head and Neck Cancer Clinical Trial
Official title:
A Phase I Study of Adjuvant OSI-774 (Tarceva®) in Patients Following Combined Chemo-Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Verified date | April 2020 |
Source | Canadian Cancer Trials Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving erlotinib after chemoradiotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of adjuvant erlotinib when given after completing chemoradiotherapy in treating patients with locally advanced squamous cell carcinoma (cancer) of the head and neck.
Status | Completed |
Enrollment | 19 |
Est. completion date | January 18, 2011 |
Est. primary completion date | December 9, 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility | DISEASE CHARACTERISTICS: - Histologically confirmed squamous cell carcinoma of the head and neck - Stage III, IVA, or IVB - Must have completed cisplatin- or carboplatin-based chemoradiotherapy within the past 4-12 weeks - Prior radiotherapy must have been given with a radical intent with receipt of at least 90% of planned dose - No evidence of disease or presence of inoperable minimal residual disease, defined by 1 of the following: - Complete response at primary tumor site and nodes (with or without nodal surgery after chemoradiotherapy) - Negative lymph node status (by physical or radiological exam) AND persistent tumefaction less than 25% of original tumor size or residual mass due to scarring - Tumor tissue samples available for EGFRvIII mutation analysis - No known brain metastasis PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-1 Life expectancy - Not specified Hematopoietic - Absolute granulocyte count = 1,500/mm^3 - Platelet count = 100,000/mm^3 Hepatic - ALT/AST < 2 times upper limit of normal (ULN) - Bilirubin < ULN (unless due to Gilbert's syndrome) Renal - Creatinine < 1.5 times ULN Cardiovascular - No myocardial infarction within the past year - No cardiac ventricular arrhythmias requiring medication - No history of cardiac disease - No uncontrolled high blood pressure - No unstable angina - No congestive heart failure Ophthalmic - No history of severe dry eye syndrome, Sjögren's syndrome, or keratoconjunctivitis sicca - No severe exposure keratopathy - No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose) - No abnormal corneal sensitivity test (Schirmer test or similar tear production test) - No disorder that might increase the risk for epithelium-related complication (e.g., bullous keratopathy, aniridia, severe chemical burns, or neutrophilic keratitis) - No congenital abnormality (e.g., Fuch's dystrophy) - No ocular inflammation or infection Gastrointestinal - Able to take oral medication - No gastrointestinal (GI) tract disease requiring IV alimentation - No uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis) - No active peptic ulcer disease Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No serious active infection - No other serious underlying medical condition that would preclude study participation - No prior allergic reaction to compounds of similar chemical or biological composition to erlotinib - No other malignancy with the past 5 years except adequately treated non-melanoma skin cancer (unless in the same area treated with radical radiotherapy) or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - See Disease Characteristics - Recovered from prior chemotherapy Endocrine therapy - Not specified Radiotherapy - See Disease Characteristics - Recovered from prior radiotherapy Surgery - See Disease Characteristics - No prior surgical procedure affecting absorption - No concurrent ophthalmic surgery Other - More than 4 weeks since other prior investigational drugs - No other concurrent investigational agents - No other concurrent anticancer therapy - Concurrent oral anticoagulants (e.g., warfarin) allowed provided there is increased vigilance with respect to INR - Concurrent nasogastric or gastrostomy tube feeding for dysphagia allowed provided there is no evidence of significant residual mucositis (i.e., > grade 1) |
Country | Name | City | State |
---|---|---|---|
Canada | London Regional Cancer Program | London | |
Canada | CHUM - Hopital Notre-Dame | Montreal |
Lead Sponsor | Collaborator |
---|---|
NCIC Clinical Trials Group | Roche Pharma AG |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Toxicity/feasibility assessed by NCI CTC v2.0 at the end of course 1 | |||
Primary | Recommended phase II dose at the end of course 1 | |||
Secondary | Correlative studies (archival and prospective) at accrual completion | |||
Secondary | Disease-free survival |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |